Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + fruquintinib + capecitabine/S-1 for third-line metastatic colorectal cancer
ChiCTR2500096938Phase 2Not yet recruiting
- Sponsor
- Nantong Cancer Hospital
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, fruquintinib, capecitabine and tegafur in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Nantong Cancer Hospital. Primary endpoint: Objective response rate. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
sintilimabfruquintinibcapecitabinetegafur
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2500096938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096938.